Related Experiment Videos
DNA testing in familial hypertrophic cardiomyopathy: clinical and laboratory implications
1Department of Molecular Genetics, Royal Prince Alfred Hospital, Camperdown, NSW, Australia.
Insights
Genetic testing for familial hypertrophic cardiomyopathy (FHC) can identify mutations in the beta-cardiac myosin heavy chain gene. This DNA-based screening found abnormalities in about 11% of families studied.
Area of Science:
- Cardiovascular Genetics
- Molecular Cardiology
- Genetic Disease Screening
Background:
- Familial hypertrophic cardiomyopathy (FHC) diagnosis is challenging due to variable clinical presentation and non-specific echocardiographic and ECG findings, especially in young individuals.
- The beta-cardiac myosin heavy chain gene has been identified as a key factor in FHC etiology since 1990, leading to advancements in understanding its molecular genetics.
Purpose of the Study:
- To evaluate the practical significance of DNA testing for FHC.
- To describe a DNA-based screening method for common mutations in the beta-cardiac myosin heavy chain gene.
Main Methods:
- Developed and applied a DNA-based screening approach.
- Targeted five frequently reported mutations within the beta-cardiac myosin heavy chain gene.
Main Results:
- The study screened randomly selected families for specific FHC-associated mutations.
- An abnormality was detected in approximately 11% of the families screened.
Conclusions:
- DNA testing offers a practical approach to identifying genetic causes of FHC.
- Screening for beta-cardiac myosin heavy chain gene mutations is a valuable tool in managing FHC families.
Abstract:
Counselling and clinical assessment in familial hypertrophic cardiomyopathy (FHC) is difficult, particularly in the young, since echocardiographic and ECG changes may not be diagnostic and clinical severity can vary. From 1990, when the beta-cardiac myosin heavy chain gene was implicated in the aetiology of FHC, considerable information about the molecular genetics of this disorder has emerged. However, an important question facing health professionals is the practical significance of DNA testing in FHC. The present study describes a DNA-based approach to screening for five commonly reported mutations involving the beta-cardiac myosin heavy chain gene. Approximately 11% of randomly selected families had an abnormality detected.